


































Peter Qi: EFFECTIVENESS OF INTERVENTIONS AT INCREASING HPV VACCINE 
INITIATION: A SYSTEMATIC REVIEW OF RECENT LITERATURE 
(Under the direction of Cynthia Feltner) 
 
While HPV vaccination is effective at reducing disease burden, vaccine uptake has been 
lackluster since initial introduction in 2006. Previous studies have not been able to conclusively 
identify effective interventions aimed at increasing vaccine uptake or initiation. The goal of this 
paper was to review recent literature (published 2014-2019) on this topic in an attempt to 
identify new effective strategies at increasing HPV vaccine initiation.  
 We found that multi-level interventions using combination strategies, such as patient 
education+reminders+improving vaccine access, were effective at significantly increasing 
vaccine initiation in populations with varied vaccination status (range +10.2% to 17.1% from 
baseline within intervention groups). The 4 Pillars Toolkit is a specific multi-level intervention 
that shows promise for application in current clinic settings. In contrast, single level 
interventions such as education or reminders alone exhibited little effectiveness at increasing 
vaccine initiation. 
 There is still a paucity of quality data reporting on the efficacy of interventions at 
increasing HPV vaccine initiation rates in special populations such as racial minorities and low-
income patients. Future reviews on this topic should ideally address these gaps in knowledge and 
also potentially provide confirmatory evidence on the effectiveness of multi-component 
interventions on other vaccination outcomes such as HPV series completion.
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Human papilloma virus (HPV) is considered one of the most common sexually 
transmitted infections, with an estimated 14 million new cases each year in the US
1
. The virus is 
responsible for approximately 90% of anal/cervical cancers as well as 70% of vaginal cancers
2
. 
The Centers for Disease Control (CDC) estimates 42,000 incident cases of HPV-related cancers 
occurred between 2011 and 2015 alone
2
. During the same time frame HPV is thought to have 
caused around 12,759 of the 18,226 incident cases of oropharyngeal cancers as well as 799 of the 
1269 incident cases of penile cancer
2
. Lesser HPV serotypes can cause genital warts which can 
affect upwards of 300,000 individuals in the US per year
1
. Although the HPV vaccine was 
introduced in 2006, vaccine uptake has remained lackluster in the US with only around 49% of 
adolescents being up to date with their HPV vaccinations in 2017
3
. Nevertheless, several studies 
have demonstrated that even vaccination rates of <50% can translate to lower population risks 




Various interventions to increase HPV vaccination rates have been evaluated, including 
educational campaigns, removing barriers to health care access, and increasing vaccine 
availability. Previous systematic reviews have reported on these interventions’ effectiveness at 
increasing HPV vaccine uptake with limited conclusiveness due to a combination of poor study 
quality and lack of general consensus among different reviews
6-9
. Furthermore, the majority of 
these reviews reported on studies published before 2015, and may not necessarily reflect the 
current vaccine intervention landscape
7-9
. Additionally, these earlier reviews predominantly 
reported on interventions that targeted females since HPV vaccine was not formally 
recommended for boys until several years after initial release. The most recent review evaluated 
studies published through January 2017 (30 studies), but was similarly unable to reach a 
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definitive conclusion on the merits of any particular intervention type due to a paucity of 
adequately powered studies and/or lack of reported vaccination outcomes
9
. Furthermore, the 
authors noted that 61% of the interventions reviewed took place in university settings with very 
few interventions targeting subpopulations that may be disproportionately affected by HPV (i.e. 
low socioeconomic status, culturally diverse groups) 
9
.    
We believe an updated review is currently justified given the continued uncertainty 
surrounding the effectiveness of interventions at promoting HPV vaccine uptake and the general 
lack of corroborating reviews on the topic. Specifically, this review will synthesize the evidence 
on the effectiveness of interventions for increasing HPV vaccine initiation in 11 to 26-year-old 
individuals in the US. To ensure results are relevant to current practice, we will focus on recent 




 Two databases were searched for relevant studies (Pubmed and EMBASE); 
ClinicalTrials.gov was also searched to identify unpublished literature. Search terms were kept 
purposefully broad to include general vaccine interventions to avoid missing universal vaccine 
intervention strategies that might also be effective for HPV vaccine uptake. A health-services 
librarian assisted in the development of the stretch strategy (shown in Appendix). Pubmed and 
EMBASE were searched on March 26, 2019, and ClinicalTrials.gov was searched on April 19, 
2019. All titles and abstracts identified in searches were imported into Covidence
10
 and 






 Inclusion and exclusion criteria can be viewed in Table 1. Eligible populations included 
those who were HPV vaccine eligible aged 9-26 years, enrolled from US settings. We included 
any intervention that aimed to increase HPV vaccine uptake. Studies that used a generalized 
intervention that targeted other vaccines (i.e. influenza uptake) were included as long as the rate 
of HPV vaccine uptake was reported as a separate outcome. Studies that included populations 
with mixed HPV vaccine status (i.e. some who initiated the series and some who have not) were 
included so long as the outcomes clearly reported data on post-intervention HPV initiation rates.  
 Studies without any comparison group were excluded as were editorials, modeling 
analyses and other qualitative theoretical studies. Studies that only assessed post-intervention 
vaccination attitudes/intent or other qualitative outcomes were excluded. Evidence from abstracts 
only (not also reported in a journal article or ClinicalTrials.gov record) were excluded 
Acceptable study designs included randomized and non-randomized clinical trials, and quality 
improvement interventions with pre- post- comparisons. Only studies from 2014-2019 were 
eligible in order to emphasize more recent literature and ensure results of the review are 
applicable to current practice. Finally, only studies performed in the US and written in English 




 was used to manage all search results. All screening was performed 
by a single reviewer. Title/abstracts were screened against criteria described above (and shown in 
Table 1). For those that were potentially relevant, the full text articles were screened against the 






 Data extraction was performed by a single reviewer using the template shown in Table 2. 
Variables of interest included type of intervention, intervention level (single vs. multi-level), 
characteristics of study setting and study sample, sample size, post-intervention vaccination rates 
as compared to baseline, and whether intervention group yielded significantly increased HPV 
vaccination initiation rates.  
Summary of Measures/Synthesis of Results 
 The primary outcome of interest was post-intervention HPV vaccine initiation rates. For 
studies that exclusively enrolled patient populations who had never received HPV vaccination, 
intervention effectiveness was determined by a comparison of post-intervention vaccination rates 
between the intervention and control groups. Interventions were deemed effective if post-
intervention vaccination rates in the intervention group were statistically higher than post-
intervention vaccination rates in the control group based on α level of 0.05. For studies that 
enrolled populations with different vaccination statuses, intervention effectiveness was 
determined based on whether the intervention group exhibited a statistically higher post-
intervention initiation rate from baseline compared to the control group. Studies were 
categorized broadly based on the level of intervention: single (education, reminders) vs. multi-
level (any combination of 2 or more strategies).    
Risk of Bias Assessment 
 Studies were assessed by a single reviewer using the templates shown in Table 3. These 
templates were adapted from the risk of bias tools published by the National Heart Lung and 
Blood Institute
11
. Important criteria included overall evaluation of selection bias, measurement 
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bias, and confounding. An overall risk of bias (low vs. high) was assigned for each study after 
considering all potential sources and severity of biases.   
Results 
Study Selection 
 Searches of Pubmed, EMBASE, and ClinicalTrials.gov produced a total of 1743 discrete 
abstracts for review. Pubmed and EMBASE yielded 1422 and 304 results, respectively. Results 
of the literature review are shown in the PRISMA diagram (Figure 1) below. After title/abstract 
screening, thirty-nine studies remained for full text review. The majority were excluded due to 
wrong outcome, In total, eight studies met full inclusion criteria. The characteristics and results 
are summarized below.  
Study Characteristics 
 Detailed study characteristics for all eight studies are shown in Table 2. Seven studies 
were randomized clinical trials while one utilized a pre-post design
12
. Five studies reported on 
single level interventions (i.e. education only or reminder only), while three studies reported on 
multi-level interventions
12-14
. Multi-level interventions typically combined education, reminder, 
and other miscellaneous strategies such as improving vaccine access. In this review, the 4 Pillars 
Toolkit was a prominent multi-level intervention which involved patient education, vaccination 
accessibility (i.e. offering vaccines at more convenient hours), streamlining clinic visits to better 
cater to vaccination (i.e. standing orders for nurses to vaccinate), and assigning a clinic 
“champion” to document progress and initiate quality improvement efforts
12,13
.  
Single level interventions were all variations of education or reminders (including 
provider prompts). Three studies took place in predominantly urban or mixed settings
12,13,15
 
while another four studies took place in safety-net hospitals/low-income settings
14,16-18
 and one 
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study took place in a university setting
19
. Of note, one study utilized culturally tailored 
interventions specifically targeting African American adolescents
16
 whereas the majority of 
studies used more generalized intervention strategies. Three studies reported on females 
only
15,16,19
 while all others reported on both males and females. Overall four studies assessed the 
effectiveness of interventions at increasing vaccine initiation rates in populations that already had 
some level of vaccine initiation. Sample sizes were variable across studies and ranged from ~200 
to >20,000. Finally, the 11-17 age group was most commonly represented.   
Risk of Bias  
The majority of studies were judged to have high risk of bias (4 of 8 included studies, 
Table 3a). Randomization procedures were often not well defined, and/or important baseline 
characteristics were either not accounted for and/or not reported between the intervention and 
control groups. For instance, several studies only accounted for basic demographic information 
such as age, insurance status, and geographical location and neglected other important 
confounders such as medical history, race, etc. Furthermore, provider blinding was often 
impossible due to the nature of certain interventions, which may have led to differential 
treatment effects in favor of the intervention group particularly in studies where the intervention 
involved face to face patient education
13,15,17
. Several studies also suffered from low subject 
recruitment and were likely underpowered. One study suffered from ~50% attrition due to 
technical issues with sending text reminders to patients
18
. Notably, the three studies that reported 
on multi-level interventions were generally of sound methodological design with adequate power 





Synthesis of results 
Single level interventions 
Five studies assessed an intervention that consisted of a single primary strategy to 
improve vaccination rates, either HPV vaccine education or a vaccination reminder strategy. 
Two studies evaluated educational strategies which comprised of online HPV educational 
content designed to provide basic information about HPV risks and stressed the importance of 
vaccination
16,19
. Reminder strategies were evaluated in one study and involved patients receiving 
text reminders to receive their HPV vaccine
18
. Two studies also investigated the effectiveness of 
using health record prompts for providers which involved a prompt in the electronic health 
record for providers to engage patients who were eligible for the vaccine
15,17
. Overall, Single 
level interventions were generally not effective at increasing post-intervention HPV vaccination 
initiation rates. Detailed results are summarized below by intervention strategy. 
The two studies assessing online educational materials aimed at increasing HPV 
vaccination rates differed in terms of population: one tailored materials to college age women
19
, 
and the other tailored materials to African American adolescents
16
; however, interventions 
assessed were similar in terms of the online educational platform and core concepts. Neither 
study found a significant difference between intervention and control group vaccine initiation 
rates (Bennett 7.8% vs. 8.7%; DiClimente 11% vs. 11%). Notably, Bennett et al exhibited a 
higher post-intervention vaccine initiation rate in its control group over its intervention group. 
 Another three studies reported on the effects of reminder interventions. Rand et al
18
 used 
simple text reminders informing patients they were due for their vaccination. Szilagyi et al
15
 used 
simple electronic health record prompts for providers to inform patients of vaccination 
eligibility. Zimet et al also used electronic health record prompts but notably included a second 
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intervention arm that had providers utilize a more elaborately phrased message with patients: “At 
this age we recommend the HPV vaccine which prevents cancer”. In contrast, the standard 
prompt that providers used was more generic: “You are due for the HPV vaccine today”. The 
elaborate phrasing provider prompt intervention was the only reminder-type strategy that proved 
significantly more effective than control intervention at increasing HPV vaccine initiation rates 




 Three studies reported on multi-level interventions
12-14
. Two (Nowalk et al and Dempsey 
et al) were RCTs, and one (Lin et al) was a pre-post study that focused on patients enrolled in the 
control arm of the RCT by Nowalk et al to assess the same intervention. Lin et al and Nowalk et 
al both reported on the effectiveness of the “4 Pillars Immunization Toolkit” (described above). 
Dempsey et al utilized a similar multi-faceted strategy that included online patient education on 
HPV, informational pamphlets, and motivational interviewing for providers on how to use a 
presumptive framing approach to address HPV vaccination
14
.  
 All three studies found that the multi-level intervention significantly increased rates of 
HPV vaccination initiation compared to the control group. Dempsey et al found a higher post-
intervention vaccination initiation rate in the intervention group (42.9%; +11.3% from baseline) 
than the control group (38.9%; +1.3% from baseline)
14
. Nowalk et al exhibited similar findings 
using the 4 Pillars Toolkit intervention with post-intervention rates of 62.7% (+10.2% baseline) 
and 69.1% (+7.3% baseline) for intervention and control groups, respectively (p<0.01)
13
. In the 
pre-post design performed by Lin et al using the control group clinics of Nowalk et al the 4 
Pillars Toolkit intervention likewise exhibited a significant increase in post-intervention HPV 







Summary of Evidence 
We identified eight studies assessing the effectiveness of recent interventions designed to 
increase HPV vaccine initiation rates. Overall, we found that multi-level interventions were 
effective at increasing HPV vaccination initiation (consistent evidence from three studies), while 
single level interventions appear to have no to small benefit (mostly consistent evidence from 
five studies). While most single level interventions such as online patient education, text 
reminders, and health record prompt reminders exhibited higher vaccine initiation rates within 
intervention group than control group, the increases were small (0 to 14% difference between 
groups) and not statistically significant. Notably, the one effective single level intervention 
utilized a message framing tactic (i.e. “The HPV vaccine is recommended because it prevents 
cancer”) rather than an educational or reminder strategy (17% difference between groups, aOR 
1.07-7.14).  
These findings mostly corroborate previous systematic reviews which also reported 
varying level of effectiveness for single level interventions such as text reminders, educational 
websites, and brief patient-provider education sessions
6-9
. One review found that reminder 
interventions that used concepts from the Health Belief Model (behavior is promoted when 
benefits are emphasized and barriers are removed) to frame a pro-vaccine message for patients 
were more successful than a generic text message or clinic reminder, particularly for patient 
populations with low health literacy
6,20
. Another review found that HPV vaccine initiation 
(starting first dose) was more strongly associated with interventions that targeted the provider 
whereas HPV vaccine completion (receiving all doses) was more associated with interventions 
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that targeted the patient (i.e. text reminders) and that optimal vaccination rates might be achieved 
with a combinatorial reminder intervention that targets both providers and patients
8
. Our findings 
appear in line with this assertion as none of the studies that reported on patient level reminder 
interventions were very effective at increasing HPV vaccine initiation compared to control. 
It is important to mention that four out of five single level interventions in this review 
were all performed in HPV vaccine naïve (0% vaccination initiation) cohorts. In most cases the 
intervention groups exhibited higher HPV initiation rates than the control groups despite not 
reaching statistical significance. For instance, in the text reminder study both females and males 
exhibited 2-5% higher initiation rates in the intervention group
18
; similarly, the provider prompt 
intervention initiation rates of 59-62% compared to 45% in the control in a population that had a 
baseline of 0% vaccine uptake
17
. Considering the goal of the Health People initiative for HPV 
vaccine uptake is 80% by 2020 a post-intervention initiation rate of ~60% seems optimistic when 
considered at face value
21
. Therefore an argument could be made that these interventions, which 
are cheap and simple to implement, could still be clinically significant despite not showing a 
definitive statistical improvement over control interventions due to being underpowered.   
In contrast to single level interventions we found that multi-level interventions (n=3) all 
significantly increased HPV vaccine initiation relative to usual care/reminder strategies
12-14
. 
Notably, these three studies were well powered (n>9000), enrolled a demographically diverse 
patient population, and exhibited effectiveness in populations with mixed HPV vaccine 
initiation. This supports the findings of previous reviews that have suggested multi-faceted 
interventions may be the most effective at increasing HPV vaccine uptake
6-9
. Notably, the 4 
Pillars Toolkit program developed by the University of Pittsburgh School of Medicine shows 





. The toolkit operates on four primary goals: increasing vaccine access, 
patient education, augmentation of clinic to optimize vaccination services, and ongoing quality 
improvement. Each of these goals can be met in a variety of different ways and can be tailored to 
the specific needs of the clinic. For instance, increasing vaccine access may entail offering clinic 
hours at more patient friendly hours (i.e. after 5pm), optimizing vaccination services may entail 
electronic medical record prompts/changes. Two of the studies that utilized this intervention also 
designated an intervention leader at each participating clinic to record intervention progress and 
make quality improvement changes as needed. The 4 Pillars Toolkit was first tailored for 
influenza vaccine but has since been well studied in recent years and deemed effective at 
increasing uptake for other routine vaccines including HPV in under vaccinated areas
12,13,23,24
. 
While Dempsey et al did not utilize the 4 Pillars Toolkit the study reported similar increases in 
HPV initiation rates (+10% intervention from baseline) using a combined educational and patient 
education intervention. This suggests that the success of the 4 Pillars Toolkit may not be special 
in and of itself but merely a reflection that multi-component interventions as a whole are more 
effective at increasing HPV vaccine initiation. Future studies would do well to provide further 
confirmatory data on the effectiveness of 4 Pillars at initiating HPV vaccination in broader 
geographic locations (current research all performed in Philadelphia) as well as shedding light on 
other implementation data such as feasibility and cost-effectiveness.  
We were able to fill in some gaps of knowledge surrounding the effectiveness of vaccine 
interventions on males. In contrast to previous reviews which reported on older interventions the 
majority of our studies (n=7) tailored interventions to both males and females including the three 
large scale studies that reported on multi-level interventions. Based off these studies it would 
appear that interventions successful at increasing HPV vaccine initiation in one gender will 
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likewise yield similar results for the other and vice versa for interventions that aren’t successful. 
We were unable to definitively conclude effectiveness data on interventions targeting other 
special demographics such as ethnic minorities and low-income populations due to the limited 
number (n=2) and methodological flaws within those studies. Historically, Caucasian adolescents 
are ~25% more likely than African American adolescents to initiate HPV vaccination
25
. 
Therefore, this is certainly an area that should receive more attention in future reviews since 
HPV initiation rates can be highly variable between different patient demographics.  
 
Strengths/Limitations 
 There are several limitations to our findings. We utilized strict inclusion criteria to 
include predominantly RCTs and recent literature only. The sole outcome of interest was post-
intervention vaccine initiation rate; we chose to exclude other outcomes such as vaccination 
intent, vaccination knowledge, and vaccination completion rates in order to provide a more 
narrow scope of focus. As a result we were only able to report on eight eligible studies. 
Furthermore, the majority of these studies had methodological flaws (i.e. underpowered) that 
limited our ability to provide definitive findings. External validity was also an issue for a 
majority of studies due to special enrollment criteria such as female only, low-income only, 
and/or culturally tailored interventions for racial minorities. Finally, we only reported on studies 
written in English and performed in the US and therefore cannot generalize any of our findings 
to foreign patient cohorts.  
 Despite these limitations this review provides crucial data in several key areas. First, it 
reinforces findings of previous reviews that multi-component interventions are the most 
successful at increasing HPV vaccine uptake. Second, we found that interventions performed in 
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more recent years appear to be expanding their scope and are targeting more diverse patient 
populations (i.e. low income, racial minorities, and males) rather than focusing exclusively on 
female adolescents.  
Conclusion 
 This review reports on the effectiveness of recent interventions at increasing HPV 
vaccine initiation rates. Overall, interventions that utilize multiple strategies seem to fare better 
than interventions that rely on a single strategy. There is still a paucity of quality data reporting 
on the efficacy of interventions at increasing HPV vaccine initiation rates in special populations 
such as racial minorities and low-income patients. Future reviews on this topic should ideally 
address these gaps in knowledge and also potentially provide confirmatory evidence on the 









Table 1. Eligibility Criteria (PICOT) 




 HPV eligible (typically girls 9-26; boys 9-21) 
 Never received any doses of HPV vaccine 
 
 HPV ineligible populations 
 Interventions exclusively targeting 
anti-vaccine populations 




 Any intervention targeted at increasing HPV 
vaccination rates 





 Compare to no intervention group 
 OR within group pre/post comparison 




 Post-intervention vaccination rates  
 
 Results from future 
projection/estimations/modeling 
 Theoretical data 
 Subjective effects (i.e. vaccination 
attitudes) 
 Outcomes that do not separate 
vaccine series initiation from 
vaccine series completion 
Timing 
 
 2014-2019   Before 2014 
Setting(s) 
 
 US  Outside of US 
Study Design(s) 
 
 Clinical trials (randomized) 
 Clinical trials (nonrandomized) 
 Pre-post studies   
 Editorials 
 Studies with no comparison group 
 Cross sectional studies/surveys 
 Unpublished literature 
 Abstract only studies 
Language 
 




Table 2. Data Extraction  
Study/design  
 
Intervention  Single vs. multi-
level intervention 
Setting Target population Sample size Post-intervention vaccination 
initiation rates (includes post-
intervention increase from 
baseline if applicable) 
Intervention 
effectiveness? (Y/N 







Control: CDC information 





Females 18-26 previously 










Intervention: text message 
reminders for HPV 
vaccination 
 
Control: general adolescent 
health text messages 
Single level 
(reminder) 
Monroe Plan for 
Medical care 
(MCO in New 
York); 39 primary 
care practices total 
Previously HPV 
unvaccinated adolescents 
aged 11-16 enrolled in the 




















≥14: 11%   
No (all p>0.05; all 







Intervention: 1) educational 
fact sheets on HPV and 
related morbidities 2) parental 
educational website (iVac) 3) 
health care provider 
communication training 
 
Control: Usual HPV 
recommendation and standard 
of care 












31.6% (post 42.9%) 
 








Intervention: 12 minute 
interactive culturally tailored 
online media presentation on 
HPV vaccination (Girls 
OnGuard) 
 
Control: 12 minute media 






waiting rooms of 5 
health clinics in 
Atlanta; eligibility 
included AA 
female and no 
previous HPV 
vaccination 
African American females 













provider prompts via EHR  
 







(PBRN) in Monroe 





consisting of 15 
pediatric clinics in 
36 states 
HPV eligible adolescents 
aged 11-17 enrolled in a 
participating clinic (post-
intervention rates assessed 
for females ONLY); 
unvaccinated and 
















baseline 64% (post 64%) 
 
Control PBRN: baseline 
67% (post 68%) 
 
Intervention CORNET: 
baseline 77% (post 82%) 
 
Control CORNET: baseline 
68% (post 75%) 
 
 







No (95% CI aOR 
0.96, 0.59-1.56) 
Zimet 2017;  
3 arm cluster 
randomized 
trial 
Arm 1: simple EHR prompt  
 
Arm 2: more elaborate EHR 
prompt with standardized 
script  
 








income families in 
Marion County, 
Indiana 
Adolescent children who 
were HPV eligible aged 
11-13 years without 
previous HPV vaccination 
Arm 1: 124 
Arm 2: 223 
Control: 301 
Arm 1: 59% 
Arm 2: 62% 
Control: 45% 
No for simple 
prompt arm 1 (95% 
CI aOR 0.5-2.48) 
 
Yes for elaborate 

















Control: Usual standard of 

















-Train a clinic 
leader to oversee 
all of the above 







adolescents aged 11-17 
with HPV vaccination 






52.5% (post 62.7%) 
 







Intervention: see above 
Nowalk 2017 
 
**Follow-up study to Nowalk 
2017 with intervention 
offered to the control clinics 
of that study 
 






clinics that served 
as control sites for 
Nowalk 2017 
Adolescents age 11-17 
(see Nowalk et al above) 





























































































No: drop outs 
were 
significantly 












































































Yes No: only 
participants 
blinded 




































































Yes Yes Yes No: providers 
would have been 
aware of which 











NA NA Yes NA Yes Not 
reported 







































































































Yes Yes Yes Yes Yes Yes Yes No Yes Yes Low 
 
**Given the often obvious nature of the vaccine interventions it is unlikely that authors and study participants would have been truly 
blinded to group assignments  
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
Records identified through 
Pubmed, EMBASE  



























Additional records identified 
through ClinicalTrials.gov 
(n =29) 
Records after 8 duplicates removed 
(n = 1743) 
Records screened 
(n = 1743) 
Records excluded 
(n = 1704) 
Full-text articles assessed 
for eligibility 
(n = 39) 
Full-text articles excluded, 
with reasons 
(n = 31) 
20 Wrong outcomes 
4 abstract exclusive 
5 wrong patient pop. 
1 wrong study design 
1 wrong comparator 
Studies included in 
qualitative synthesis 
(n = 8) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n =  NA) 
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Appendix 1: Search strategy 
For Pubmed the search criteria was “((immunization programs[majr] OR (immunization* OR 
vaccine* OR vaccinat*) AND (rate*[tiab] OR adher*[tiab] OR uptake*[tiab]) AND (rct OR rcts 
OR "randomized control" OR "Randomized controlled" OR randomized controlled trial[pt] OR 
clinical trial[pt] OR "clinical trial" OR "clinical trials"))”. Pubmed filters included human trials 
only, English only, and publication date 2014-2019. For EMBASE the search criteria was 
“(immunization* OR vaccine* OR vaccinat*) AND (rate* OR adher* OR uptake*) AND 
('randomized controlled trial'/exp OR rcts OR rct OR 'randomized control' OR 'randomized 
controlled' OR 'clinical trial'/exp OR 'clinical trial' OR 'clinical trials'/exp OR 'clinical trials') 
AND (2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py) AND ([adolescent]/lim OR 
[child]/lim) AND [embase]/lim NOT [medline]/lim”. For ClinicalTrials.gov the search criteria 
was “childhood vaccinations” filtered for age 0-17 and 18-64, completed trials only, and 
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